The Responsible Care Programme: our commitment to sustainability

Responsible Care is the global chemical-pharmaceutical industry's unifying commitment to the safe management of chemicals throughout their life cycle, while promoting their role in improving quality of life and contributing to sustainable development.


Pharma-Cooperation-Code: Disclosure obligation

In 2017, the signatory companies have disclosed cooperation expenditures to an amount of just over CHF 153 million. For further information.

Corporate Social Responsibility (CSR) from the point of view of scienceindustries


  • The member companies of scienceindustries are aware of their social responsib­ility and take this seriously - for decades, they have voluntarily got involved in a wide range of fields in CSR activities related to issues such as protecting the environment, promoting education and fighting corruption.
  • The international community has created a multi-faceted set of CSR regulations incorporating guidelines and conduct recommendations for multinational companies. G­overnment commitments beyond this are not a productive approach. Solo action on the part of Switzerland would be ineffective and would put an unnecessary strain on our country as a business location.
  • Greater juridification of CSR and particularly the broadening of public liability for multinational companies - as provided by the Responsible Business Initiative - would be counter-productive. Rather, it is a question of increasing the responsibility of the economy itself.
Position paper - Demands with regard to Switzerland's European policy

Switzerland is a part of Europe from a cultural, geographical and economic point of view and has shared values. From an economic policy perspective, the bilateral approach is a story of success, which should be continued. The European Union is by far the most important trade partner for Chemistry Pharma Biotech, Switzerland's largest research and export industry.

Swiss National Bank poses major challenges to export industry

The surprise decision of the Swiss National Bank to discontinue the minimum exchange rate of CHF 1.20 per Euro poses major challenges to Switzerland‘s largest export industry Chemistry Pharma Biotech.

Although the extent of the strengthening of the Swiss franc against other major currencies is still uncertain, the measure will without any doubt have a negative impact on the price competitiveness of our exports. Not only will this dim the growth prospects, but it may also lead to structural adjustments in the companies of our industry.

We hope the Swiss National Bank will prevent an excessive strengthening of the Swiss franc. Against this new background, additional burdens on the economy in the form of new regulation projects, such as for example the Energy Strategy 2050, should be avoided by all means.

more Your Website for Science and Technology

scienceindustries Sustainability Report 2012

This brief report from scienceindustries – the business association chemistry pharma biotech – aims to present the activities and services of the chemical and pharmaceutical industry within several se-lected areas of sustainability. However, it should also demonstrate those objectives that sciencein-dustries companies are aiming for as a whole. Finally, we also look forward to receiving suggestions, as a result of this report, from our target audience in the political, business and science sector on how we can improve our measures of sustainability.


No to route proposed by the «Energy Strategy 2050»

The federal government's «Energy Strategy 2050» jeopardizes the security of electricity supplies and the competitiveness of Switzerland’s exporting industry. scienceindustries is therefore fundamentally opposed to the «Energy Strategy 2050».

Leading business association changes its name to scienceindustries

In future, scienceindustries will be the new name for the business association previously known as SGCI Chemie Pharma Schweiz. The new name emphasizes the outstanding ability to innovate of the biggest Swiss export industry and on its commitment to make Switzerland a world leading site for production, research and business in the fields of chemicals, pharmaceuticals and biotech.